Leukemia rates among Iraqi children soaring
A study published in the American Journal of Public Health entitled "Trends in Childhood Leukemia in Basrah, Iraq (1993-2007)" reminds us all of what we already knew: in most wars, kids are the biggest losers.
According to the research, the rates of pediatric leukemia among Iraqi children living in and around the Basra area have more than doubled since 1993. During the years studied, this area was incredibly unstable, enduring the brunt of the Iran-Iraq war, the US-led operation to drive Iraq out of Kuwait in 1991, and most recently the 2003 US-led invasion.
The study was completed as part of an extended agreement between Baghdad's Mustansiriya University, Basrah University, and the Fred Hutchinson Cancer Research Center in Washington state.
Source: Madicalnewstoday
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
